- Home
- ACET vs CRT Comparison
ACET vs CRT Comparison
Compare ACET & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- CRT
- Stock Information
- Founded
- ACET 1947
- CRT 1991
- Country
- ACET United States
- CRT United States
- Employees
- ACET N/A
- CRT N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- CRT Oil & Gas Production
- Sector
- ACET Health Care
- CRT Energy
- Exchange
- ACET Nasdaq
- CRT Nasdaq
- Market Cap
- ACET 70.3M
- CRT 64.0M
- IPO Year
- ACET N/A
- CRT 1992
- Fundamental
- Price
- ACET $0.72
- CRT $11.76
- Analyst Decision
- ACET Buy
- CRT
- Analyst Count
- ACET 6
- CRT 0
- Target Price
- ACET $6.00
- CRT N/A
- AVG Volume (30 Days)
- ACET 324.2K
- CRT 33.8K
- Earning Date
- ACET 03-06-2025
- CRT 01-01-0001
- Dividend Yield
- ACET N/A
- CRT 8.46%
- EPS Growth
- ACET N/A
- CRT N/A
- EPS
- ACET N/A
- CRT 0.95
- Revenue
- ACET N/A
- CRT $6,623,430.00
- Revenue This Year
- ACET N/A
- CRT N/A
- Revenue Next Year
- ACET N/A
- CRT N/A
- P/E Ratio
- ACET N/A
- CRT $12.97
- Revenue Growth
- ACET N/A
- CRT N/A
- 52 Week Low
- ACET $0.69
- CRT $8.88
- 52 Week High
- ACET $2.40
- CRT $14.98
- Technical
- Relative Strength Index (RSI)
- ACET 37.26
- CRT 54.29
- Support Level
- ACET $0.74
- CRT $11.60
- Resistance Level
- ACET $0.91
- CRT $13.31
- Average True Range (ATR)
- ACET 0.06
- CRT 0.57
- MACD
- ACET -0.00
- CRT 0.09
- Stochastic Oscillator
- ACET 12.61
- CRT 40.61
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States based trust. Its principal asset is the net profits interests. The net profits interests are derived from producing royalty, overriding royalty interests, and working interests properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.